Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Net loss	$ (10,540)	$ (27,689)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	1	2
In-process research and development	0	30,117
Noncash transaction costs shared with Seneca	0	(135)
Noncash lease expense	140	122
Gain on forgiveness of PPP loan	0	(279)
Accretion of debt discount and non-cash interest expense	0	2,334
Loss on issuance of LBS Series 1 Preferred Stock	0	1,881
Loss on issuance of secured debt	0	686
Loss on issuance of warrants	1,110	3,247
Change in fair value of warrant liabilities	(2,403)	(17,939)
Change in fair value of share liability	0	(91)
Stock-based compensation	946	1,208
Other	(213)	191
Changes in operating assets and liabilities
Other receivables	0	84
Prepaid and other assets and other noncurrent assets	744	(1,264)
Accounts payable and accrued liabilities	706	(2,145)
Accrued compensation	(418)	(1,544)
Operating lease liabilities	(127)	(122)
Net cash used in operating activities	(10,054)	(11,718)
Cash flows from investing activities:
Cash acquired in connection with the Merger	0	3,279
Acquisition related costs paid	0	(3,333)
Net cash used in investing activities	0	(54)
Cash flows from financing activities
Payments on debt	(524)	(949)
Proceeds from issuance of debt	0	1,250
Proceeds from issuance of LBS Series 1 Preferred Stock	0	19,900
Proceeds from issuance of common stock and warrants	14,401	5,209
Redemption of warrants	0	(99)
Payment of equity issuance costs	(333)	0
Payment of debt issuance costs	0	(148)
Net cash provided by financing activities	13,544	25,163
Net (decrease) increase in cash, cash equivalents and restricted cash	3,490	13,391
Cash, cash equivalents and restricted cash, beginning of period	10,521	739
Cash, cash equivalents and restricted cash, end of period	14,011	14,130
Reconciliation of cash, cash equivalents and restricted cash to the balance sheets
Cash and cash equivalents	13,985	14,104
Restricted cash	26	26
Total cash, cash equivalents and restricted cash	14,011	14,130
Supplemental disclosure of cash flows
Interest Paid	10	61
Right-of-use assets obtained in exchange for lease liabilities	355	0
Supplemental disclosures of non-cash investing and financing activities
Equity issuance costs included in accounts payable and accrued liabilities	683	67
Issuance of common stock for the cashless exercise of warrants	1,274	0
Fair value of warrants issued to placement agent	55	0
Fair value of warrants issued to underwriter agent	459	0
Issuance of common stock upon conversion of Series B Convertible Preferred Stock	58	0
Insurance financing arrangements included in prepaid and other assets	784	772
Purchase of property and equipment included in accounts payable and accrued liabilities	10	0
Transaction costs shared with Seneca	0	135
Acquisition costs related to stock issuance	0	1,184
Issuance of common stock to former Seneca stockholders	0	28,728
Conversion of LBS Series C Preferred stock into common stock	0	9,503
Net assets acquired in the Merger	0	2
Acquisition related vesting of RSU’s assumed in the Merger	0	41
Acquisition related fair value change in warrant liability assumed in the Merger	$ 0	$ 51